| Trial ID: | L1640 |
| Source ID: | NCT00560300
|
| Associated Drug: |
1 Alpha D2
|
| Title: |
Regulation of Bone Formation in Renal Osteodystrophy
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Secondary Hyperparathyroidism|Renal Osteodystrophy
|
| Interventions: |
DRUG: 1 alpha D2|DRUG: 1,25 dihydroxy vitamin D3|DRUG: Sevelamer HCl|DRUG: Calcium Carbonate
|
| Outcome Measures: |
Primary: Bone Formation Rate, 8 months | Secondary: Bone histomorphometric parameters other than bone formation rate, biochemical parameters (phosphorus, calcium, PTH, alkaline phosphatase, FGF-23, vitamin D dose), 8 months
|
| Sponsor/Collaborators: |
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
61
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2000-11
|
| Completion Date: |
2006-11
|
| Results First Posted: |
|
| Last Update Posted: |
2010-01-14
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00560300
|
